Key Points
- Director Huda Zoghbi sold 1,638 shares on Feb. 19 at an average of $781.33 for about $1.28M, cutting her stake by 49.03% to 1,703 shares, according to an SEC filing.
- Regeneron raised its quarterly dividend to $0.94 (from $0.88), with an ex-dividend date of Feb. 20 and payment on Mar. 5, equal to a $3.76 annualized payout and roughly a 0.5% yield.
- The company beat expectations for the quarter with EPS $11.44 versus $10.74 expected and revenue $3.88B versus $3.76B expected, with revenue up 2.5% year-over-year and a net margin of 31.41%.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Huda Zoghbi sold 1,638 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Regeneron Pharmaceuticals Trading Up 0.9%
NASDAQ:REGN opened at $787.04 on Tuesday. The stock has a fifty day simple moving average of $769.67 and a 200 day simple moving average of $676.28. The firm has a market capitalization of $83.21 billion, a price-to-earnings ratio of 18.94, a price-to-earnings-growth ratio of 2.09 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts' consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm earned $12.07 earnings per share. The business's quarterly revenue was up 2.5% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.05%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MV Capital Management Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $60,000. Wick Capital Partners LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $507,000. Compound Planning Inc. raised its stake in shares of Regeneron Pharmaceuticals by 69.3% in the 4th quarter. Compound Planning Inc. now owns 1,676 shares of the biopharmaceutical company's stock valued at $1,294,000 after acquiring an additional 686 shares in the last quarter. Invesco Ltd. lifted its holdings in Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company's stock worth $1,228,127,000 after purchasing an additional 106,632 shares during the last quarter. Finally, Birchwood Financial Partners Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $32,000. Institutional investors own 83.31% of the company's stock.
Analysts Set New Price Targets
Several brokerages have issued reports on REGN. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating on the stock in a research note on Monday, February 2nd. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an "overweight" rating in a research report on Monday, February 2nd. Zacks Research lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 6th. Royal Bank Of Canada lifted their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a "sector perform" rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, February 16th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $793.81.
Get Our Latest Stock Analysis on REGN
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
